Access and Coverage: Data and Clinical Development

Decisions about coverage and access are influenced by the type and strength of evidence generated during and after clinical development. This session will examine how clinical and real-world data intersect with payer and coverage considerations, and why early alignment between development strategies and evidence needs is particularly important in rare diseases.

Moderator: Pamela Gavin, CEO, NORD 

Panelists:

• Ravi Pathak, PhD, MBA, Medical Director, Lysosomal Storage Disorders, US Medical, Takeda
• Mark Trusheim, MS, Senior Strategy Advisor, NEWDIGS, Tufts Medical Center
• Margarita Valdez Martinez, Chief Advocacy Officer, ASGCT
• Danny Yeh, PhD, Vice President, Rare Disease, Center of Excellence, AESARA

View PDF Presentation from this Session